Develops targeted immunotherapies for autoimmune, neurodegenerative and eye diseases by blocking the classical complement pathway.
10-K for FY2025, filed Mar 30, 2026
No revenue reported yet.
10-K for FY2025, filed Mar 30, 2026
10-Q for Q3 FY2026, filed Nov 9, 2026
−$51.2MView ↗
Portfolio priorities
The older report described active programs across GBS, Huntington’s disease, GA and autoimmune indications. The latest report emphasizes late-stage candidates for GBS and GA alongside an oral drug for autoimmune conditions.
10-K for FY2022, filed Mar 6, 2023 10-K for FY2025, filed Mar 30, 2026Guillain-Barré Syndrome, or GBS: We are advancing our lead candidate, ANX005, an investigational, full-length monoclonal antibody, or mAb…View ↗
Huntington’s Disease, or HD: We are evaluating ANX005 for the potential treatment of patients with HD, a slowly progressing, inherited and…View ↗
Geographic Atrophy, or GA: We are evaluating ANX007, an antigen-binding fragment, or Fab, formulated for intravitreal administration, for…View ↗
ANX1502 for Autoimmune Indications: ANX1502 is a novel oral small molecule targeting classical complement, which we believe is…View ↗
Our strategic priorities include advancing two late-stage registrational programs: tanruprubart, toward our first potential approval in…View ↗
Competes with Hansa Biopharma, AstraZeneca, Alexion, argenx, Apellis, Astellas, Regeneron, Aviceda Therapeutics, Janssen, Novartis, Perceive Bio, Roche, Alkeus, Belite Bio, Stealth BioTherapeutics, Boehringer Ingelheim, Galimedix Therapeutics, Cognition Therapeutics, ONL Therapeutics, and Ocugen
10-K for FY2025, filed Mar 30, 2026There are currently no approved therapies for GBS in the United States. IVIg and PE are the most commonly used therapies in the Western…View ↗
Loading...